Rapid Genetic Testing for Newly Diagnosed Breast Cancer Patients Phase II Study Screening Form
Thank you for your interest in the Rapid Genetic Testing for Newly Diagnosed Breast Cancer Patients Phase II Study or Rapid Genetic Testing 2 Study for short.
This research study provides rapid genetic testing for 9 genes associated with increased risk of breast cancer and other cancers to women newly diagnosed with breast cancer. The 9 genes tested through the study are BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53, ATM, or CHEK2.
Participation involves providing a saliva sample for genetic testing by Invitae (a genetic testing company located in the United States). Results will be made available to the genetic counsellor at Women's College Hospital 5-12 days after receipt of your saliva sample at the Invitae laboratory. When the results are available, the genetic counsellor will call you to give you your results. You will also be asked to complete 4 questionnaires over two years (one questionnaire at the time of enrollment and three follow-up questionnaires).
If you are interested in participating in the study, please complete the screening questions below to determine if you are eligible to participate.